Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

WHO advises against two drugs for treatment of non-severe Covid-19

The WHO Guideline Development Group (GDG) has put out new guidance advising against the use of fluvoxamine and colchicine for patients with mild or moderate Covid-19.

The WHO Guideline Development Group (GDG) has put out new guidance advising against the use of fluvoxamine and colchicine for patients with mild or moderate Covid-19. Fluvoxamine (an antidepressant) and colchicine (a gout drug) are commonly used, inexpensive drugs that have received considerable interest as potential Covid-19 treatments during the pandemic. However, there has been ongoing uncertainty about the overall benefits and safety profile of these drugs. Insufficient evidence that the drugs improve important outcomes, and both carry potential harms In making their decision, the GDG looked at data from three randomised controlled trials (RCTs) involving over 2,000 patients on

---------------------------

This content is restricted to members of Pavilion Health Today. If you are an existing user, please log in. New users may register for free below.

Existing Users Log In
   
New User Registration
captcha
*Required field
author avatar
Lauren Nicolle
Lauren is a qualified journalist who writes primarily across the health and social care sectors. She is passionate about exposing the injustices faced by people with a learning disability, with a particular focus on equal access to healthcare.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy